Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

DOI DOI PubMed オープンアクセス

この論文をさがす

説明

<jats:p>(Abstracted from <jats:italic toggle="yes">N Engl J Med</jats:italic> 2019;381:1929–1939)</jats:p> <jats:p>The National Comprehensive Cancer Network recommends secondary cytoreduction for ovarian cancer patients with recurrent disease who have received no treatment for a period of 6 months following a complete response from prior chemotherapy. Retrospective reviews and meta-analyses have shown the most benefit from this operation in those with platinum-sensitive disease and those with little or no postoperative residual disease.</jats:p>

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ